van Dyck CH, et al. - Among participants with mild Alzheimer disease, researchers ascertained if AZD0530 (saracatinib) is safe and well-tolerated and if it can slow the decline in cerebral metabolic rate for glucose (CMRgl). Of the 159 patients included, 79 were randomly allocated to AZD0530 and 80 to placebo. The data showed that, in participants with mild Alzheimer's disease, a 100-mg to 125-mg daily dose of AZD0530 is adequately safe and well-tolerated. In this 52-week randomized clinical trial, the authors were unable to detect statistically significant effects of AZD530 treatment on the relative decline of CMRgl in a region of interest related to Alzheimer's disease or secondary clinical or biomarker gauges. However, as measured by ¹⁸F-FDG PET, this trial supports the use of CMRgl as a statistically robust outcome measure which associated with clinical outcomes. Diarrhea and other gastrointestinal disorders were the most frequent adverse events.